Rapidly growing mycobacteria and Nocardia/aerobic Actinomycetes can cause a variety of serious infections, particularly in immunocompromised patients. Resistance, toxicity, intolerance, and therapeutic failures may occur with traditional empiric treatment with drugs of choice. Antimicrobial susceptibility testing, especially with newer agents, may help to guide appropriate therapeutic choices. Capreomycin is a key antimycobacterial drug in treatment of extensively drug-resistant tuberculosis (XDR-TB). Drug susceptibility testing (DST) for capreomycin is not routinely performed in newly diagnosed XDR-TB. Extensively drug resistant tuberculosis (XDR-TB) is the most drug-resistant form of TB and is defined as M. tuberculosis (MTB) resistant to isoniazid, rifampicin, any fluoroquinolone drug and at least one of the three second-line injectable agents kanamycin, amikacin, and capreomycin. A key component of the current XDR-TB treatment regimen is capreomycin, an injectable antimycobacterial agent in the cyclic peptide class.
No special preparation is needed for Afb Mtb - Capreomycin Disk Diffusion Infected Tissue. Inform your doctor if you are on any medications or have any underlying medical conditions or allergies before undergoing Afb Mtb - Capreomycin Disk Diffusion Infected Tissue. Your doctor depending on your condition will give specific instructions.
|UNISEX||All age groups||A result where the drug is sensitive indicates that the patient responds to this antibiotic|